Investors

Latest Announcements

Press Release

Woke and University of Sydney Sign Term Sheet for Phase II trial of WP002 Psilocybin in Alcohol Use Disorder

Read More
Press Release

Provisional Patent Application

Read More
Press Release

Woke and Swinburne University Sign Memorandum of Understanding to Develop WP002 Psilocybin-assisted Psychotherapy Phase IIB trial in Treatment-Resistant Depression

Read More
Press Release

Woke and QIMR Berghofer Sign Letter of Intent for Clinical Trial of WP002 Psilocybin in Prolonged Grief

Read More

Latest Presentations

Presentation

December 2022 Corporate Presentation

Read More

Latest Media

Media

Biotech Daily: Dr Boreham's Crucible on Woke

Read More
Media

Woke setting sights on Australian IPO in 2023

Read More
Media

Potential Therapeutic Benefits of Psychedelics

Read More
Media

Can microdosing psychedelics improve your mental health? Here's what the science says

Read More

ACN: 651 290 729

Address: Suite 301, 10 Bridge St, Sydney NSW 2000 Australia

Email: info@wokeph.com